US20010047082A1 - Soluble keratin peptide - Google Patents
Soluble keratin peptide Download PDFInfo
- Publication number
- US20010047082A1 US20010047082A1 US09/899,372 US89937201A US2001047082A1 US 20010047082 A1 US20010047082 A1 US 20010047082A1 US 89937201 A US89937201 A US 89937201A US 2001047082 A1 US2001047082 A1 US 2001047082A1
- Authority
- US
- United States
- Prior art keywords
- water
- recited
- filtrate
- peptide
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention is related generally to water-soluble peptides. More specifically, the present invention is related to water-soluble peptides derived from keratin. In particular, the present invention is related to water-soluble peptides formed from chemically processed hair, which can be used as wound-healing agents
- Chronic wounds can be caused by a variety of events, including surgery, prolonged bedrest and traumatic injuries. Partial thickness wounds can include second degree bums, abrasions, and skin graft donor sites. Healing of these wounds can be problematic, especially in cases of diabetes mellitus or chronic immune disorders. Full thickness wounds have no skin remaining, and can be the result of trauma, diabetes (e.g., leg ulcers) and venous stasis disease, which can cause full thickness ulcers of the lower extremities. Full thickness wounds tend to heal very slowly or not at all. Proper wound care technique including the use of wound dressings is extremely important to successful chronic wound management. Chronic wounds affect an estimated four million people a year, resulting in health care costs in the billions of dollars. T.
- the wound-healing process involves a complex series of biological interactions at the cellular level which can be grouped into three phases: homeostasis and inflammation; granulation tissue formation and reepithelization; and remodeling.
- R. A. F. Clark “Cutaneous Tissue Repair: Basic Biological Considerations,” J. Am. Acad. Dermatol , Vol. 13, pp. 701-725 (1985).
- Keratinocytes epidermal cells that manufacture and contain keratin
- Growth factors such as transforming growth factor- ⁇ (TGF- ⁇ ) play a critical role in stimulating the migration process. The migration occurs optimally under the cover of a moist layer.
- TGF- ⁇ transforming growth factor- ⁇
- Keratins have also been found to be necessary for reepithelization. Specifically, keratin types K5 and K14 have been found in the lower, generating, epidermal cells, and types K1 and K10 have been found in the upper, differentiated cells. I. K. Cohen, R. F. Diegleman, and W. J. Lindblad, eds., Wound Healing: Biochemical and Clinical Aspects , W. W. Saunders Company, 1992. Keratin types K6 and K10 are believed to be present in healing wounds, but not in normal skin. Keratins are major structural proteins of all epithelial cell types and appear to play a major role in wound healing.
- An optimum wound dressing would protect the injured tissue, maintain a moist environment, be water permeable, maintain microbial control, deliver healing agents to the wound site, be easy to apply, not require frequent changes and be non-toxic and non-antigenic.
- several wound dressings are currently on the market, including occlusive dressings, non-adherent dressings, absorbent dressings, and dressings in the form of sheets, foams, powders and gels. S. Thomas, Wound Management and Dressing , The Pharmaceutical Press, London, 1990.
- a water-soluble peptide derived from a keratinous source such as hair and methods for making same are provided.
- One method includes providing a keratinous material having disulfide linkages and oxidizing the keratinous material with an oxidizing agent, such that some disulfide linkages are cleaved and oxidized, forming water-soluble peptides.
- the water-soluble peptides can be separated, collected, dried, and used as a wound-healing agent.
- a preferred source of keratinous material is hair, such as human hair.
- hair is oxidized with a sufficient concentration of oxidizing agent for a sufficient time and temperature so as to cleave a significant portion of the hair disulfide bonds, such that some disulfide bonds are oxidized to form hydrophilic groups such as sulfonic acid and such that water-soluble peptides are produced.
- oxidizing agents include, but are not limited to, hydrogen peroxide, peracetic acid, percarbonates, persulfates, chlorine dioxide, sodium and calcium peroxides, perborates, and hypochlorite.
- the oxidized hair can be filtered, the filtrate collected, and neutralized with base.
- Water soluble peptides from the neutralized filtrate can be precipitated from solution by mixing the filtrate with a water-miscible organic solvent such as methanol.
- the precipitate can be collected using centrifugation and the collected filtrate dried. In one method, about 20 percent of the original hair mass is collected as peptide material after drying.
- the dried precipitate can be ground into a fine powder.
- Peptides produced according to the present invention are largely water soluble and have an average molecular weight of about 850 daltons and an average chain length of about 10 amino acids.
- the peptide chains are believed to have attached a hydrophilic group, for example, an ionizable group such as sulfonic acid.
- most peptides are believed to have at least one sulfonic acid group formed from the oxidization of disulfide linkages of hair.
- One product made according to the present invention is a powder that is whitish to yellow in color and readily soluble in water.
- the peptide powder can be placed over a wound as a powder.
- the peptide powder can also be formulated into any water-based solution, cream, gel, or other vehicle for convenient application to a wound.
- a peptide solution could be incorporated into or cast onto a polymer wound dressing or a keratin wound dressing sheet for application to a wound.
- the peptide wound-healing agent was shown to enhance proliferation of human skin keratinocytes, human dermal fibroblasts, and microvascular endothelial cells. Applicants believe that the peptide fraction isolated according to the present invention is a highly active form of a wound-healing agent.
- FIG. 1 is a chromatogram showing the molecular weight distribution of one sample of the soluble peptide made according to the present invention.
- FIG. 2 is a table of experimental results illustrating proliferation of cells critical to the wound-healing process after application of a keratin peptide wound-healing agent made according to the present invention.
- the present invention provides a wound-healing agent which can include a peptide having an ionizable pendant group such as sulfonic acid which can be derived from an oxidized protein disulfide linkage.
- a preferred source of protein is keratin.
- One preferred source of keratin is hair. While hair is a preferred source of keratinous material, other keratinous materials such as animal hair, skin, beaks, hooves, feathers, and nails are also suitable for use in the present invention.
- the patient or a human donor are some preferred sources of hair, as hair from these sources is most likely to result in a non-antigenic wound-healing product, although animal hair may be acceptable for many individuals.
- hair is provided, preferably clean and unbleached.
- the hair is washed with Versa-Clean TM (Fisher Scientific, Pittsburgh, Pa.), rinsed with deionized water, and dried.
- the hair can be oxidized in peracetic acid or another suitable reagent such as H 2 O 2 .
- One method utilizes between about 1% to 32% peracetic acid, at a temperature between about 0 degrees C and 100 degrees C for between 0.5 and 24 hours.
- One method treats 30 grams of hair with 500 mL of 4 volume percent peracetic acid at 4 degrees C for 24 hours.
- Another method treats the hair at room temperature for 24 hours.
- Yet another method treats the hair at about 90 degrees C for about 10 hours.
- the hair is treated by boiling the hair in the oxidizing agent for at least about 2 hours, and preferably for about 5 hours. The higher oxidizing temperature is believed to produce higher yields relative to the lower oxidizing temperature.
- At least 5, 10, and 15 weight percent of the original hair weight is eventually recovered as peptides by application of sufficient oxidant, heat, and time. In one embodiment, about 20 weight percent of the original hair can be eventually recovered as peptides, useful for the present invention.
- the treatment with oxidizing agent is believed to open the cuticle structure of the hair and to swell the keratin.
- Treatment with oxidizing agent e.g., H 2 O 2 and peracetic acid
- Treatment with oxidizing agent is believed to at least partially oxidize the naturally occurring disulfide linkages to produce a protein with cysteic acid side groups (—CH 2 SO 3 H), which are also referred to as sulfonic acid groups in the present application.
- the treatment with oxidizing agent is not believed to break a substantial portion of peptide backbone bonds.
- the result is believed to include short-chain peptides that have at least one ionizable pendant group such as sulfonic acid, where the peptides are soluble in water at physiological pH.
- the present invention includes the production of water-soluble peptides from a keratinous material including peptides having hydrophilic groups such as sulfonic acid groups.
- the oxidized hair can be recovered, for example with filtration through a coarse fritted glass filter, and the filtrate collected. Filtration thus separates the water-soluble peptides from the remaining keratin source such as hair, allowing collection of the water-soluble peptides in the filtrate. While filtration is a preferred separation method, other suitable separation methods such as decantation or dialysis are also within the scope of the invention.
- the hair can be rinsed numerous times with deionized water to increase the amount of soluble protein that is washed off the hair. The hair can be discarded or kept for other uses.
- the filtrate in one embodiment is concentrated about ten-fold using vacuum distillation, leaving a viscous syrup.
- the filtrate is concentrated until the concentrated filtrate contains about 120 grams of peptide per liter.
- One vacuum distillation method uses between about 5 and 10 mm Hg pressure at a pot temperature of about 40 degrees C. In some methods, concentration is performed at a later stage of the process.
- the filtrate can be neutralized using a base.
- the filtrate is neutralized to facilitate the precipitation of the peptides.
- 3 to 4 normal ammonium hydroxide is used as a base in the amount of about 0.1 mL to 1 mL of the viscous syrup formed from concentrating the filtrate.
- about 1 mL of base is added to 100 mL of unconcentrated filtrate. The base can be added until the pH is about 7.
- Neutralized filtrate can then be mixed with a water-miscible organic solvent such as methanol, ethanol, acetone, or tetrahydrofuran.
- a water-miscible organic solvent such as methanol, ethanol, acetone, or tetrahydrofuran.
- about 6 to 10 mL of methanol is added to 1 mL of the viscous syrup containing the concentrated filtrate.
- about 60 to 100 mL of methanol is added to 1 mL of the unconcentrated filtrate.
- the water-soluble peptide has lower solubility in the organic solvent/water mixture and cleanly precipitates out.
- the precipitate can then be collected using well known methods such as centrifugation, filtration, or decanting.
- the precipitate can then be dried using evaporation, preferably without the application of heat.
- the precipitate is dried at room temperature.
- the precipitate is dried under vacuum, again without the application of heat. No grinding is required, as the precipitate obtained, when dry, is already a powder.
- the dried precipitate is further processed by grinding into a fine powder using a mortar and pestle or equivalent grinding instrument.
- the powder obtained from one method is whitish to yellow in color and is completely soluble in water. Analysis of these samples have shown them to be Gaussian distributions of low molecular weight peptides, as shown in the chromatogram of FIG. 1. Elemental analysis has shown the carbon content to be between 38.39 and 41.59 weight percent; the hydrogen content to be between 5.74 and 6.16 weight percent; the nitrogen content to be between 15.19 and 15.89 weight percent; the oxygen content to be between 23.67 and 26.97 weight percent; and the sulfur content to be between 3.80 and 4.78 weight percent. Analysis of mass spectra shows a distribution of molecular weight species, centered at approximately 850 daltons.
- the peptide provided by the present invention can be used in several applications.
- the skin healing properties of the peptide can be used to promote healing, repair, and cell growth in keratinous tissue generally.
- the peptide can be used to treat damaged skin and skin wounds including, for example, rashes, including diaper rash, bums including sunburn, cuts, abrasions, punctures, sores including bed sores, ulcers including diabetic ulcers and other skin injuries or irritations.
- the peptide can also be used to treat aging, weakened or damaged skin, including, for example, wrinkled skin.
- the keratinous tissue is damaged tissue located either externally or internally.
- an external wound can be treated by applying the peptide to the wound.
- the peptide is admixed with a cream, lotion, or gel before application to the skin.
- the peptide is added to a keratin hydrogel prior to application to the skin.
- a keratin hydrogel can be made according to, for example, U.S. patent application Ser. No. 08/979,456, filed Nov. 26, 1997, entitled KERATIN-BASED HYDROGEL FOR BIOMEDICAL APPLICATIONS AND METHOD OF PRODUCTION.
- the peptide can be added to a wound dressing prior to application.
- the peptide can be added to a keratin sheet as described in U.S. patent application Ser. No. 08/979,526, filed Nov.
- the peptide can be applied internally to damaged keratinous tissue lining the GI tract by orally administering the peptide. Examples of such damage can result from ulcers, colitis, or Crohn's disease.
- the peptide can also be added as a cell growth stimulant to a tissue engineering scaffold such as the sheet described in U.S. patent application Ser. No. 09/198,998, filed Nov. 24, 1998, entitled METHOD OF CROSS-LINKING KERATIN-BASED FILMS, SHEETS, AND BULK MATERIALS.
- the peptide is believed suitable to speed repair of sun or weather damaged skin.
- the peptide can be mixed with a carrier lotion such as lanolin and applied to the skin.
- the peptide can also be added to cosmetics to impart a skin healing property to the cosmetic. Cosmetic bases are believed suitable for inclusion of peptides made according to the present invention.
- the purpose of this study was to assess cell proliferation as a result of their exposure to the keratin peptide, relative to no exposure (media alone) and to known stimulants for each cell type, the “positive control.” Exposure to media alone was considered the baseline of the study, so the average number of cells in the baseline cultures was subtracted out of the average number of cells in the cultures containing the soluble peptides and the positive control for each cell line. This process mathematically reduces the baseline to zero and everything else becomes relative to zero, as seen in the first column of data. These subtracted numbers are divided through by the average baseline value and become a percent above or below baseline. The numbers in the table represent the percent above baseline.
- the keratin-derived peptide stimulated growth of the selected cell lines and compares favorably with the known growth factors for each cell line.
- skin keratinocytes grew over 28% percent more than with media alone, and at 5 micrograms peptide per milliliter, dermal fibroblasts grew over 12 percent more relative to the baseline.
- dermal fibroblasts grew over 12 percent more relative to the baseline.
- microvascular endothelial cells grew more than 9 percent more than the media only baseline.
- Application of the keratin-derived peptide is thus believed to be useful as a wound-healing agent.
Abstract
Description
- The present application is related to U.S. Pat. No. 5,358,935 entitled NONANTIGENIC KERATINOUS PROTEIN MATERIAL; U.S. patent application Ser. No. 09/057,161, filed Apr. 8, 1998, entitled KERATINOUS PROTEIN MATERIAL FOR WOUND HEALING APPLICATIONS AND METHOD; U.S. patent application Ser. No. 08/979,456, filed Nov. 26, 1997, entitled KERATIN-BASED HYDROGEL FOR BIOMEDICAL APPLICATIONS AND METHOD OF PRODUCTION; U.S. patent application Ser. No. 08/979,526, filed Nov. 26, 1997, entitled KERATIN-BASED SHEET MATERIAL FOR BIOMEDICAL APPLICATIONS AND METHOD OF PRODUCTION; and U.S. patent application Ser. No. 09/198,998, filed Nov. 24, 1998, entitled METHOD OF CROSSLINING KERATIN-BASED FILMS, SHEETS AND BULK MATERIALS, entitled WATER ABSORBENT KERATIN AND GEL FORMED THEREFROM, all of which are herein incorporated by reference.
- The present invention is related generally to water-soluble peptides. More specifically, the present invention is related to water-soluble peptides derived from keratin. In particular, the present invention is related to water-soluble peptides formed from chemically processed hair, which can be used as wound-healing agents
- Chronic wounds can be caused by a variety of events, including surgery, prolonged bedrest and traumatic injuries. Partial thickness wounds can include second degree bums, abrasions, and skin graft donor sites. Healing of these wounds can be problematic, especially in cases of diabetes mellitus or chronic immune disorders. Full thickness wounds have no skin remaining, and can be the result of trauma, diabetes (e.g., leg ulcers) and venous stasis disease, which can cause full thickness ulcers of the lower extremities. Full thickness wounds tend to heal very slowly or not at all. Proper wound care technique including the use of wound dressings is extremely important to successful chronic wound management. Chronic wounds affect an estimated four million people a year, resulting in health care costs in the billions of dollars. T. Phillips, O. Kehinde, and H. Green, “Treatment of Skin Ulcers with Cultivated Epidermal Allografts,”J. Am. Acad. Dermatol, V. 21, pp. 191-199 (1989).
- The wound-healing process involves a complex series of biological interactions at the cellular level which can be grouped into three phases: homeostasis and inflammation; granulation tissue formation and reepithelization; and remodeling. R. A. F. Clark, “Cutaneous Tissue Repair: Basic Biological Considerations,”J. Am. Acad. Dermatol, Vol. 13, pp. 701-725 (1985). Keratinocytes (epidermal cells that manufacture and contain keratin) migrate from wound edges to cover the wound. Growth factors such as transforming growth factor-β (TGF-β) play a critical role in stimulating the migration process. The migration occurs optimally under the cover of a moist layer. Keratins have also been found to be necessary for reepithelization. Specifically, keratin types K5 and K14 have been found in the lower, generating, epidermal cells, and types K1 and K10 have been found in the upper, differentiated cells. I. K. Cohen, R. F. Diegleman, and W. J. Lindblad, eds., Wound Healing: Biochemical and Clinical Aspects, W. W. Saunders Company, 1992. Keratin types K6 and K10 are believed to be present in healing wounds, but not in normal skin. Keratins are major structural proteins of all epithelial cell types and appear to play a major role in wound healing.
- An optimum wound dressing would protect the injured tissue, maintain a moist environment, be water permeable, maintain microbial control, deliver healing agents to the wound site, be easy to apply, not require frequent changes and be non-toxic and non-antigenic. Although not ideal for chronic wounds, several wound dressings are currently on the market, including occlusive dressings, non-adherent dressings, absorbent dressings, and dressings in the form of sheets, foams, powders and gels. S. Thomas,Wound Management and Dressing, The Pharmaceutical Press, London, 1990.
- Attempts have been made to provide improved dressings that would assist in the wound-healing process using biological materials such as growth factors. These biologicals have proven very costly and, due to the lack of an appropriate delivery vehicle, have shown minimal clinical relevance in accelerating the chronic wound-healing process relative to their cost. In cases of severe full thickness wounds, autografts (skin grafts from the patient's body) are often used. Although the graft is non-antigenic, it must be harvested from a donor site on the patient's body, creating an additional wound. In addition, availability of autologous tissue may not be adequate. Allografts (skin grafts from donors other than the patient) are also used when donor sites are not an option. Allografts essentially provide a “wound dressing” that provides a moist, water-permeable layer, but are rejected by the patient, usually within two weeks, and do not become part of the new epidermis.
- What would be advantageous is a non-toxic, non-antigenic, inexpensive wound-healing agent having the ability to accelerate the rate of wound healing and allow non-healing wounds to heal.
- A water-soluble peptide derived from a keratinous source such as hair and methods for making same are provided. One method includes providing a keratinous material having disulfide linkages and oxidizing the keratinous material with an oxidizing agent, such that some disulfide linkages are cleaved and oxidized, forming water-soluble peptides. The water-soluble peptides can be separated, collected, dried, and used as a wound-healing agent. A preferred source of keratinous material is hair, such as human hair.
- In one method, hair is oxidized with a sufficient concentration of oxidizing agent for a sufficient time and temperature so as to cleave a significant portion of the hair disulfide bonds, such that some disulfide bonds are oxidized to form hydrophilic groups such as sulfonic acid and such that water-soluble peptides are produced. Examples of oxidizing agents include, but are not limited to, hydrogen peroxide, peracetic acid, percarbonates, persulfates, chlorine dioxide, sodium and calcium peroxides, perborates, and hypochlorite. The oxidized hair can be filtered, the filtrate collected, and neutralized with base. Water soluble peptides from the neutralized filtrate can be precipitated from solution by mixing the filtrate with a water-miscible organic solvent such as methanol. The precipitate can be collected using centrifugation and the collected filtrate dried. In one method, about 20 percent of the original hair mass is collected as peptide material after drying. The dried precipitate can be ground into a fine powder.
- Peptides produced according to the present invention are largely water soluble and have an average molecular weight of about 850 daltons and an average chain length of about 10 amino acids. The peptide chains are believed to have attached a hydrophilic group, for example, an ionizable group such as sulfonic acid. In particular, most peptides are believed to have at least one sulfonic acid group formed from the oxidization of disulfide linkages of hair. One product made according to the present invention is a powder that is whitish to yellow in color and readily soluble in water.
- In use, the peptide powder can be placed over a wound as a powder. The peptide powder can also be formulated into any water-based solution, cream, gel, or other vehicle for convenient application to a wound. In addition, a peptide solution could be incorporated into or cast onto a polymer wound dressing or a keratin wound dressing sheet for application to a wound. In in vitro trials, the peptide wound-healing agent was shown to enhance proliferation of human skin keratinocytes, human dermal fibroblasts, and microvascular endothelial cells. Applicants believe that the peptide fraction isolated according to the present invention is a highly active form of a wound-healing agent.
- FIG. 1 is a chromatogram showing the molecular weight distribution of one sample of the soluble peptide made according to the present invention; and
- FIG. 2 is a table of experimental results illustrating proliferation of cells critical to the wound-healing process after application of a keratin peptide wound-healing agent made according to the present invention.
- The present invention provides a wound-healing agent which can include a peptide having an ionizable pendant group such as sulfonic acid which can be derived from an oxidized protein disulfide linkage. A preferred source of protein is keratin. One preferred source of keratin is hair. While hair is a preferred source of keratinous material, other keratinous materials such as animal hair, skin, beaks, hooves, feathers, and nails are also suitable for use in the present invention. The patient or a human donor are some preferred sources of hair, as hair from these sources is most likely to result in a non-antigenic wound-healing product, although animal hair may be acceptable for many individuals. In one method according to the present invention, hair is provided, preferably clean and unbleached. In another method, the hair is washed with Versa-Clean TM (Fisher Scientific, Pittsburgh, Pa.), rinsed with deionized water, and dried.
- The hair can be oxidized in peracetic acid or another suitable reagent such as H2O2. One method utilizes between about 1% to 32% peracetic acid, at a temperature between about 0 degrees C and 100 degrees C for between 0.5 and 24 hours. One method treats 30 grams of hair with 500 mL of 4 volume percent peracetic acid at 4 degrees C for 24 hours. Another method treats the hair at room temperature for 24 hours. Yet another method treats the hair at about 90 degrees C for about 10 hours. In a preferred method, the hair is treated by boiling the hair in the oxidizing agent for at least about 2 hours, and preferably for about 5 hours. The higher oxidizing temperature is believed to produce higher yields relative to the lower oxidizing temperature. In various embodiments, at least 5, 10, and 15 weight percent of the original hair weight is eventually recovered as peptides by application of sufficient oxidant, heat, and time. In one embodiment, about 20 weight percent of the original hair can be eventually recovered as peptides, useful for the present invention. The treatment with oxidizing agent is believed to open the cuticle structure of the hair and to swell the keratin. Treatment with oxidizing agent (e.g., H2O2 and peracetic acid) is believed to at least partially oxidize the naturally occurring disulfide linkages to produce a protein with cysteic acid side groups (—CH2SO3H), which are also referred to as sulfonic acid groups in the present application. The treatment with oxidizing agent is not believed to break a substantial portion of peptide backbone bonds. The result is believed to include short-chain peptides that have at least one ionizable pendant group such as sulfonic acid, where the peptides are soluble in water at physiological pH. In general, the present invention includes the production of water-soluble peptides from a keratinous material including peptides having hydrophilic groups such as sulfonic acid groups.
- The oxidized hair can be recovered, for example with filtration through a coarse fritted glass filter, and the filtrate collected. Filtration thus separates the water-soluble peptides from the remaining keratin source such as hair, allowing collection of the water-soluble peptides in the filtrate. While filtration is a preferred separation method, other suitable separation methods such as decantation or dialysis are also within the scope of the invention. The hair can be rinsed numerous times with deionized water to increase the amount of soluble protein that is washed off the hair. The hair can be discarded or kept for other uses. The filtrate in one embodiment is concentrated about ten-fold using vacuum distillation, leaving a viscous syrup. In one method, the filtrate is concentrated until the concentrated filtrate contains about 120 grams of peptide per liter. One vacuum distillation method uses between about 5 and 10 mm Hg pressure at a pot temperature of about 40 degrees C. In some methods, concentration is performed at a later stage of the process.
- The filtrate can be neutralized using a base. The filtrate is neutralized to facilitate the precipitation of the peptides. In one method, 3 to 4 normal ammonium hydroxide is used as a base in the amount of about 0.1 mL to 1 mL of the viscous syrup formed from concentrating the filtrate. In another method, about 1 mL of base is added to 100 mL of unconcentrated filtrate. The base can be added until the pH is about 7.
- Neutralized filtrate can then be mixed with a water-miscible organic solvent such as methanol, ethanol, acetone, or tetrahydrofuran. In one embodiment, about 6 to 10 mL of methanol is added to 1 mL of the viscous syrup containing the concentrated filtrate. In another embodiment, about 60 to 100 mL of methanol is added to 1 mL of the unconcentrated filtrate. The water-soluble peptide has lower solubility in the organic solvent/water mixture and cleanly precipitates out.
- The precipitate can then be collected using well known methods such as centrifugation, filtration, or decanting. The precipitate can then be dried using evaporation, preferably without the application of heat. In one method, the precipitate is dried at room temperature. In another method, the precipitate is dried under vacuum, again without the application of heat. No grinding is required, as the precipitate obtained, when dry, is already a powder. In some embodiments, the dried precipitate is further processed by grinding into a fine powder using a mortar and pestle or equivalent grinding instrument.
- The powder obtained from one method is whitish to yellow in color and is completely soluble in water. Analysis of these samples have shown them to be Gaussian distributions of low molecular weight peptides, as shown in the chromatogram of FIG. 1. Elemental analysis has shown the carbon content to be between 38.39 and 41.59 weight percent; the hydrogen content to be between 5.74 and 6.16 weight percent; the nitrogen content to be between 15.19 and 15.89 weight percent; the oxygen content to be between 23.67 and 26.97 weight percent; and the sulfur content to be between 3.80 and 4.78 weight percent. Analysis of mass spectra shows a distribution of molecular weight species, centered at approximately 850 daltons.
- The peptide provided by the present invention can be used in several applications. The skin healing properties of the peptide can be used to promote healing, repair, and cell growth in keratinous tissue generally. The peptide can be used to treat damaged skin and skin wounds including, for example, rashes, including diaper rash, bums including sunburn, cuts, abrasions, punctures, sores including bed sores, ulcers including diabetic ulcers and other skin injuries or irritations. The peptide can also be used to treat aging, weakened or damaged skin, including, for example, wrinkled skin. In one use, the keratinous tissue is damaged tissue located either externally or internally. In one example of use, an external wound can be treated by applying the peptide to the wound. In one method, the peptide is admixed with a cream, lotion, or gel before application to the skin. In another method, the peptide is added to a keratin hydrogel prior to application to the skin. A keratin hydrogel can be made according to, for example, U.S. patent application Ser. No. 08/979,456, filed Nov. 26, 1997, entitled KERATIN-BASED HYDROGEL FOR BIOMEDICAL APPLICATIONS AND METHOD OF PRODUCTION. In another method, the peptide can be added to a wound dressing prior to application. For example, the peptide can be added to a keratin sheet as described in U.S. patent application Ser. No. 08/979,526, filed Nov. 26, 1997, ENTITLED KERATIN-BASED SHEET MATERIAL FOR BIOMEDICAL APPLICATIONS AND METHOD OF PRODUCTION. In another use of the invention, the peptide can be applied internally to damaged keratinous tissue lining the GI tract by orally administering the peptide. Examples of such damage can result from ulcers, colitis, or Crohn's disease.
- The peptide can also be added as a cell growth stimulant to a tissue engineering scaffold such as the sheet described in U.S. patent application Ser. No. 09/198,998, filed Nov. 24, 1998, entitled METHOD OF CROSS-LINKING KERATIN-BASED FILMS, SHEETS, AND BULK MATERIALS. The peptide is believed suitable to speed repair of sun or weather damaged skin. The peptide can be mixed with a carrier lotion such as lanolin and applied to the skin. The peptide can also be added to cosmetics to impart a skin healing property to the cosmetic. Cosmetic bases are believed suitable for inclusion of peptides made according to the present invention.
- Referring now to the table in FIG. 2, cell studies were performed on human skin keratinocytes, human dermal fibroblasts, and microvascular endothelial cells, as indicated, to determine the effect of the keratin peptide on proliferation of cells critical to the wound-healing process. Known growth factors for each cell line were used as positive controls. The following concentrations of keratin peptide were used: 0 (control, media alone); 0.005; 0.01; 0.05; 0.1; 0.5; 1; 5; and 10 micrograms per milliliter. At
day 5 of the study, the cells were analyzed using a technique that counts the number of cells. The purpose of this study was to assess cell proliferation as a result of their exposure to the keratin peptide, relative to no exposure (media alone) and to known stimulants for each cell type, the “positive control.” Exposure to media alone was considered the baseline of the study, so the average number of cells in the baseline cultures was subtracted out of the average number of cells in the cultures containing the soluble peptides and the positive control for each cell line. This process mathematically reduces the baseline to zero and everything else becomes relative to zero, as seen in the first column of data. These subtracted numbers are divided through by the average baseline value and become a percent above or below baseline. The numbers in the table represent the percent above baseline. - As can be seen from inspection of FIG. 2, the keratin-derived peptide stimulated growth of the selected cell lines and compares favorably with the known growth factors for each cell line. In particular, at 0.5 micrograms per milliliter of peptide, skin keratinocytes grew over 28% percent more than with media alone, and at 5 micrograms peptide per milliliter, dermal fibroblasts grew over 12 percent more relative to the baseline. At 0.05 micrograms of peptide per milliliter of media, microvascular endothelial cells grew more than 9 percent more than the media only baseline. Application of the keratin-derived peptide is thus believed to be useful as a wound-healing agent.
- Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of reagents, concentrations, and step order, without exceeding the scope of the invention. The inventions's scope is, of course, defined in the language in which the appended claims are expressed.
Claims (54)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/899,372 US20010047082A1 (en) | 1999-06-11 | 2001-07-02 | Soluble keratin peptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/330,550 US6270791B1 (en) | 1999-06-11 | 1999-06-11 | Soluble keratin peptide |
US09/899,372 US20010047082A1 (en) | 1999-06-11 | 2001-07-02 | Soluble keratin peptide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/330,550 Continuation US6270791B1 (en) | 1999-06-11 | 1999-06-11 | Soluble keratin peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010047082A1 true US20010047082A1 (en) | 2001-11-29 |
Family
ID=23290261
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/330,550 Expired - Lifetime US6270791B1 (en) | 1999-06-11 | 1999-06-11 | Soluble keratin peptide |
US09/899,372 Abandoned US20010047082A1 (en) | 1999-06-11 | 2001-07-02 | Soluble keratin peptide |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/330,550 Expired - Lifetime US6270791B1 (en) | 1999-06-11 | 1999-06-11 | Soluble keratin peptide |
Country Status (7)
Country | Link |
---|---|
US (2) | US6270791B1 (en) |
EP (1) | EP1265570B1 (en) |
JP (1) | JP2003501208A (en) |
AT (1) | ATE281842T1 (en) |
CA (1) | CA2376889A1 (en) |
DE (1) | DE60015807T2 (en) |
WO (1) | WO2000076437A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274165A1 (en) * | 2006-02-17 | 2008-11-06 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US20090004242A1 (en) * | 2006-02-17 | 2009-01-01 | Van Dyke Mark E | Coatings and Biomedical Implants Formed From Keratin Biomaterials |
US20090211593A1 (en) * | 2007-10-05 | 2009-08-27 | Peter Coppola | Reactive Keratin Protein Formulations and Methods of Using for Revitalizing Hair |
WO2013025941A1 (en) * | 2011-08-17 | 2013-02-21 | Keranetics Llc | Low protein percentage gelling compositions |
US9827245B2 (en) | 2013-03-15 | 2017-11-28 | KeraNetics, LLC | Keratin compositions comprising halofuginone |
US10385095B2 (en) | 2011-08-17 | 2019-08-20 | Keratin Biosciences, Inc | Methods for extracting keratin proteins |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
DE10051983A1 (en) * | 2000-10-20 | 2002-06-13 | Beate Kehrel | Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36, |
WO2003035722A1 (en) * | 2001-09-25 | 2003-05-01 | Southwest Research Institute | Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same |
ES2426420T3 (en) * | 2002-01-28 | 2013-10-23 | Keraplast Technologies Ltd. | Bioactive Keratin Peptides |
US8394371B2 (en) | 2002-02-11 | 2013-03-12 | Neocutis Sa | Compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
US7001987B2 (en) * | 2002-04-22 | 2006-02-21 | Keraplast Technologies, Ltd. | Hydrogel with controllable mechanical, chemical, and biological properties and method for making same |
US6989437B2 (en) * | 2002-04-10 | 2006-01-24 | Keraplast Technologies, Ltd. | Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks |
US6914126B2 (en) * | 2002-04-10 | 2005-07-05 | Keraplast Technologies, Ltd. | Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks |
US20040082717A1 (en) * | 2002-06-24 | 2004-04-29 | Southwest Research Institute | Keratin-silicone copolymers and interpenetrating networks (IPN's), methods of production and methods of use thereof |
US7439012B2 (en) * | 2004-08-17 | 2008-10-21 | Wake Forest University Health Sciences | Ambient stored blood plasma expanders containing keratose |
US20060058238A1 (en) | 2004-09-15 | 2006-03-16 | Lee Laurent-Applegate | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
JP2006151940A (en) * | 2004-10-29 | 2006-06-15 | Dainichiseika Color & Chem Mfg Co Ltd | Cell activator |
US8920827B2 (en) | 2005-10-21 | 2014-12-30 | Wake Forest University Health Sciences | Keratin bioceramic compositions |
US7892573B2 (en) * | 2006-02-10 | 2011-02-22 | Wake Forest University Health Sciences | Nerve regeneration employing keratin biomaterials |
JP2008019244A (en) * | 2006-06-13 | 2008-01-31 | Dainichiseika Color & Chem Mfg Co Ltd | Cell activation agent |
CA2683015C (en) * | 2007-04-17 | 2016-11-08 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US20090047260A1 (en) * | 2007-08-17 | 2009-02-19 | Wake Forest University Health Sciences | Keratin biomaterials for cell culture and methods of use |
US9068162B2 (en) | 2007-08-17 | 2015-06-30 | Wake Forest University Health Sciences | Keratin biomaterials for cell culture and methods of use |
JP2012526845A (en) | 2009-05-13 | 2012-11-01 | ケラプラスト テクノロジーズ, リミテッド | Biopolymer material |
CN102497779A (en) * | 2009-07-02 | 2012-06-13 | 凯拉普雷斯特技术有限公司 | Nutritional supplement |
JP2013521313A (en) * | 2010-03-05 | 2013-06-10 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | Controlled delivery system |
US8545893B2 (en) * | 2010-03-08 | 2013-10-01 | Wake Forest University Health Sciences | Keratin biomaterials for treatment of ischemia |
WO2012068376A2 (en) | 2010-11-17 | 2012-05-24 | Wake Forest University Health Sciences | Keratin compositions for treatment of bone deficiency or injury |
JP2017516869A (en) * | 2014-06-04 | 2017-06-22 | ジム バイオサイエンシズ,インコーポレイテッド | Compositions and methods for improving skin quality |
KR20170050327A (en) * | 2015-10-30 | 2017-05-11 | 주식회사 코스메카코리아 | Cosmetic compositions for anti-aging comprising keratin peptide as an efficient component |
KR102311325B1 (en) | 2020-01-08 | 2021-10-14 | 주식회사 에이더블유바이오 | Cosmetic Composition for Moisturizing or Improving Elasticity of Skin Comprising Low Molecular and Polar Keratin Peptides as Active Ingredients |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1214299A (en) * | 1915-06-30 | 1917-01-30 | William M Grosvenor | Manufacturing colloids. |
US2434688A (en) * | 1942-11-03 | 1948-01-20 | Ralph L Evans | Regenerated keratin |
US2445028A (en) * | 1944-11-07 | 1948-07-13 | Us Agriculture | Method of dispersing keratin proteins with amides and the composition resulting therefrom |
US2517572A (en) * | 1948-11-23 | 1950-08-08 | Chase B Jones | Process of utilizing detergents to solubilize keratin materials |
US2814851A (en) * | 1953-12-11 | 1957-12-03 | Rubberset Company | Keratin treating process and products thereof |
US3033755A (en) * | 1961-04-14 | 1962-05-08 | Kolmar Laboratories | Process for removing the water soluble materials from a keratin structure and cosmetic or pharmaceutical product formed therefrom |
US3642498A (en) * | 1969-09-18 | 1972-02-15 | Gen Mills Inc | Method of preparing keratin-containing films and coatings |
US3655416A (en) * | 1968-12-18 | 1972-04-11 | Lever Brothers Ltd | Lipid-protein membrane and process |
US4178361A (en) * | 1973-09-10 | 1979-12-11 | Union Corporation | Sustained release pharmaceutical composition |
US4357274A (en) * | 1981-08-06 | 1982-11-02 | Intermedicat Gmbh | Process for the manufacture of sclero protein transplants with increased biological stability |
US4423032A (en) * | 1981-02-05 | 1983-12-27 | Kao Soap Co., Ltd. | Hair treatments |
US4495173A (en) * | 1980-11-28 | 1985-01-22 | Kao Soap Co., Ltd. | Pre-shampoo type hair treatment composition |
US4570629A (en) * | 1982-03-17 | 1986-02-18 | University Of Illinois Foundation | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same |
US4751074A (en) * | 1980-11-17 | 1988-06-14 | Kao Soap Co., Ltd. | Hair rinse composition |
US4895722A (en) * | 1981-03-03 | 1990-01-23 | Kao Soap Co., Ltd. | Hair treatments |
US4959213A (en) * | 1983-11-09 | 1990-09-25 | L'oreal | Pharmaceutical composition for treatment and/or prevention of diseases of the skin involving an inflammatory process |
US5047249A (en) * | 1988-07-22 | 1991-09-10 | John Morris Co., Inc. | Compositions and methods for treating skin conditions and promoting wound healing |
US5300285A (en) * | 1992-10-13 | 1994-04-05 | Dow Corning Corporation | Permanent waving with silicones |
US5314873A (en) * | 1990-05-18 | 1994-05-24 | Morinaga Milk Industry Co., Ltd. | Milk-protein hydrolyzates and compositions for use as hair and skin treating agent |
US5320796A (en) * | 1992-04-30 | 1994-06-14 | Dow Corning Toray Silicone Co., Ltd. | Method for the preparation of powder mixtures |
US5634945A (en) * | 1995-03-02 | 1997-06-03 | Pernia; Luis R. | Biological filler and use of same |
US5679819A (en) * | 1995-04-04 | 1997-10-21 | Croda International Plc | Cystine-silicone copolymers and their use for treating keratin substrates |
US5712252A (en) * | 1996-03-08 | 1998-01-27 | The University Of Tennessee Research Corporation | Method of augmenting soft tissue in mammals |
US5763583A (en) * | 1993-05-24 | 1998-06-09 | Kao Corporation | Process for producing solubilized protein |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US6270793B1 (en) * | 1999-09-13 | 2001-08-07 | Keraplast Technologies, Ltd. | Absorbent keratin wound dressing |
US6274155B1 (en) * | 1999-09-13 | 2001-08-14 | Keraplast Technologies, Ltd. | Nonwoven sheet and film containing water absorbent keratin |
US6461628B1 (en) * | 1999-09-13 | 2002-10-08 | Keraplast Technologies, Ltd. | Non-woven keratin cell scaffold |
US6506732B1 (en) * | 1999-01-28 | 2003-01-14 | Universite Laval | Enzymatic hydrolysate of milk proteins |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US7001987B2 (en) * | 2002-04-22 | 2006-02-21 | Keraplast Technologies, Ltd. | Hydrogel with controllable mechanical, chemical, and biological properties and method for making same |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE531446C (en) * | 1929-11-08 | 1931-08-10 | Eduard Lingel Schuhfabrik A G | Seam for footwear and process for their manufacture |
BE498020A (en) * | 1949-09-15 | |||
US2993794A (en) | 1958-06-25 | 1961-07-25 | Gen Foods Corp | Process for preparing keratin protein |
US3842848A (en) | 1971-05-27 | 1974-10-22 | Wilson Sinclair Co | Keratin polypeptide hydrolyzates as hair treating agents |
JPS537760A (en) | 1976-07-12 | 1978-01-24 | Agency Of Ind Science & Technol | Modified keratin membrane |
DE2705669C3 (en) | 1977-02-11 | 1982-02-25 | Röhm GmbH, 6100 Darmstadt | Process for the production of water-soluble hydrolysis products from raw materials containing keratin |
JPS603104B2 (en) | 1977-03-07 | 1985-01-25 | 積水化学工業株式会社 | Improved method for producing keratin-containing materials |
JPS57144211A (en) | 1981-03-04 | 1982-09-06 | Kao Corp | Emulsified cosmetic |
JPS57149211A (en) | 1981-03-10 | 1982-09-14 | Kao Corp | Solubilized cosmetic |
JPS5846011A (en) | 1981-09-14 | 1983-03-17 | Kao Corp | Hair treatment |
FR2521571B1 (en) * | 1982-02-17 | 1986-07-18 | Oreal | KERATINIC POLYMER WITH S-SULFOCYSTEIN RESIDUES, PREPARATION METHOD THEREOF AND TREATMENT COMPOSITION THEREOF |
FR2540381B1 (en) | 1983-02-08 | 1986-05-30 | Dior Sa Parfums Christian | METHOD FOR STIMULATING CELL GROWTH; COSMETIC COMPOSITION, PHARMACEUTICAL AND COMPLEMENTARY COMPOSITION FOR CELL CULTURE MEDIUM APPLYING THIS PROCESS |
JPS59155248A (en) * | 1983-02-22 | 1984-09-04 | テルモ株式会社 | Coating membrane and production thereof |
DE3470457D1 (en) * | 1983-02-25 | 1988-05-26 | Kao Corp | Hair cosmetics |
US4711780A (en) | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
US4983580A (en) * | 1986-04-04 | 1991-01-08 | Allergan, Inc. | Methods and materials for use in corneal wound healing |
US4818520A (en) | 1986-10-15 | 1989-04-04 | Edmund M. Jaskiewicz | Keratin hydrolysate formulations and methods of preparation thereof |
US5258043A (en) * | 1987-07-20 | 1993-11-02 | Regen Corporation | Method for making a prosthetic intervertebral disc |
FR2609393A1 (en) | 1988-02-23 | 1988-07-15 | Serobiologiques Lab Sa | Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared |
JPH0721061B2 (en) * | 1988-08-13 | 1995-03-08 | 株式会社ニッピ | Method for producing water-soluble keratin protein |
FR2661414B1 (en) | 1990-04-25 | 1995-03-24 | Michel Jean Pierre | PRODUCT BASED ON MODIFIED KERATINS, ITS PREPARATION PROCESS AND ITS APPLICATIONS IN PARTICULAR IN HUMAN OR VETERINARY MEDICINE. |
US5276138A (en) * | 1990-09-17 | 1994-01-04 | Kurashiki Boseki Kabushiki Kaisha | Process for solubilizing animal hair |
JPH04308515A (en) * | 1991-04-03 | 1992-10-30 | Seiwa Kasei:Kk | Cosmetic composition |
ZA919777B (en) | 1991-07-23 | 1992-09-30 | Curtis Helene Ind Inc | Composition and method for protecting hair against thermal degradation and to aid in hair styling |
DK0970701T3 (en) | 1991-11-20 | 2006-03-06 | Innogenetics Nv | Pellets derived from keratinocytes for use as wound healing agents |
EP0648264A4 (en) * | 1992-06-03 | 1997-10-01 | Univ Case Western Reserve | Bandage for continuous application of biologicals. |
JP3283302B2 (en) * | 1992-09-22 | 2002-05-20 | 株式会社成和化成 | Method for producing reduced keratin |
US5358935A (en) * | 1992-11-19 | 1994-10-25 | Robert Allen Smith | Nonantigenic keratinous protein material |
JPH0959124A (en) * | 1995-08-18 | 1997-03-04 | Kondo Toshio | Production of ultraviolet-ray-cutting agent and cosmetic containing the same |
RU2106154C1 (en) | 1996-08-16 | 1998-03-10 | Василий Александрович Мензул | Wound dressing material |
JP2000281539A (en) * | 1999-01-29 | 2000-10-10 | Seiwa Kasei:Kk | Cosmetic base |
-
1999
- 1999-06-11 US US09/330,550 patent/US6270791B1/en not_active Expired - Lifetime
-
2000
- 2000-06-09 EP EP00942727A patent/EP1265570B1/en not_active Expired - Lifetime
- 2000-06-09 WO PCT/US2000/015905 patent/WO2000076437A1/en active IP Right Grant
- 2000-06-09 AT AT00942727T patent/ATE281842T1/en not_active IP Right Cessation
- 2000-06-09 JP JP2001502779A patent/JP2003501208A/en active Pending
- 2000-06-09 DE DE60015807T patent/DE60015807T2/en not_active Expired - Lifetime
- 2000-06-09 CA CA002376889A patent/CA2376889A1/en not_active Abandoned
-
2001
- 2001-07-02 US US09/899,372 patent/US20010047082A1/en not_active Abandoned
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1214299A (en) * | 1915-06-30 | 1917-01-30 | William M Grosvenor | Manufacturing colloids. |
US2434688A (en) * | 1942-11-03 | 1948-01-20 | Ralph L Evans | Regenerated keratin |
US2445028A (en) * | 1944-11-07 | 1948-07-13 | Us Agriculture | Method of dispersing keratin proteins with amides and the composition resulting therefrom |
US2517572A (en) * | 1948-11-23 | 1950-08-08 | Chase B Jones | Process of utilizing detergents to solubilize keratin materials |
US2814851A (en) * | 1953-12-11 | 1957-12-03 | Rubberset Company | Keratin treating process and products thereof |
US3033755A (en) * | 1961-04-14 | 1962-05-08 | Kolmar Laboratories | Process for removing the water soluble materials from a keratin structure and cosmetic or pharmaceutical product formed therefrom |
US3655416A (en) * | 1968-12-18 | 1972-04-11 | Lever Brothers Ltd | Lipid-protein membrane and process |
US3642498A (en) * | 1969-09-18 | 1972-02-15 | Gen Mills Inc | Method of preparing keratin-containing films and coatings |
US4178361A (en) * | 1973-09-10 | 1979-12-11 | Union Corporation | Sustained release pharmaceutical composition |
US4751074A (en) * | 1980-11-17 | 1988-06-14 | Kao Soap Co., Ltd. | Hair rinse composition |
US4495173A (en) * | 1980-11-28 | 1985-01-22 | Kao Soap Co., Ltd. | Pre-shampoo type hair treatment composition |
US4423032A (en) * | 1981-02-05 | 1983-12-27 | Kao Soap Co., Ltd. | Hair treatments |
US4895722A (en) * | 1981-03-03 | 1990-01-23 | Kao Soap Co., Ltd. | Hair treatments |
US4357274A (en) * | 1981-08-06 | 1982-11-02 | Intermedicat Gmbh | Process for the manufacture of sclero protein transplants with increased biological stability |
US4570629A (en) * | 1982-03-17 | 1986-02-18 | University Of Illinois Foundation | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same |
US4959213A (en) * | 1983-11-09 | 1990-09-25 | L'oreal | Pharmaceutical composition for treatment and/or prevention of diseases of the skin involving an inflammatory process |
US5047249A (en) * | 1988-07-22 | 1991-09-10 | John Morris Co., Inc. | Compositions and methods for treating skin conditions and promoting wound healing |
US5314873A (en) * | 1990-05-18 | 1994-05-24 | Morinaga Milk Industry Co., Ltd. | Milk-protein hydrolyzates and compositions for use as hair and skin treating agent |
US5320796A (en) * | 1992-04-30 | 1994-06-14 | Dow Corning Toray Silicone Co., Ltd. | Method for the preparation of powder mixtures |
US5300285A (en) * | 1992-10-13 | 1994-04-05 | Dow Corning Corporation | Permanent waving with silicones |
US5763583A (en) * | 1993-05-24 | 1998-06-09 | Kao Corporation | Process for producing solubilized protein |
US5634945A (en) * | 1995-03-02 | 1997-06-03 | Pernia; Luis R. | Biological filler and use of same |
US5679819A (en) * | 1995-04-04 | 1997-10-21 | Croda International Plc | Cystine-silicone copolymers and their use for treating keratin substrates |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5712252A (en) * | 1996-03-08 | 1998-01-27 | The University Of Tennessee Research Corporation | Method of augmenting soft tissue in mammals |
US6506732B1 (en) * | 1999-01-28 | 2003-01-14 | Universite Laval | Enzymatic hydrolysate of milk proteins |
US6270793B1 (en) * | 1999-09-13 | 2001-08-07 | Keraplast Technologies, Ltd. | Absorbent keratin wound dressing |
US6274155B1 (en) * | 1999-09-13 | 2001-08-14 | Keraplast Technologies, Ltd. | Nonwoven sheet and film containing water absorbent keratin |
US6461628B1 (en) * | 1999-09-13 | 2002-10-08 | Keraplast Technologies, Ltd. | Non-woven keratin cell scaffold |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US7001987B2 (en) * | 2002-04-22 | 2006-02-21 | Keraplast Technologies, Ltd. | Hydrogel with controllable mechanical, chemical, and biological properties and method for making same |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274165A1 (en) * | 2006-02-17 | 2008-11-06 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US20090004242A1 (en) * | 2006-02-17 | 2009-01-01 | Van Dyke Mark E | Coatings and Biomedical Implants Formed From Keratin Biomaterials |
US10821211B2 (en) | 2006-02-17 | 2020-11-03 | Wake Forest University Health Sciences | Coatings and biomedical implants formed from keratin biomaterials |
US20110142910A1 (en) * | 2006-02-17 | 2011-06-16 | Van Dyke Mark E | Clotting and Healing Compositions Containing Keratin Biomaterials |
US8258093B2 (en) | 2006-02-17 | 2012-09-04 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US8273702B2 (en) | 2006-02-17 | 2012-09-25 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US8299013B2 (en) | 2006-02-17 | 2012-10-30 | Wake Forest University Health Sciences | Clotting and healing compositions containing keratin biomaterials |
US9149566B2 (en) * | 2006-02-17 | 2015-10-06 | Wake Forest University Health Sciences | Coatings and biomedical implants formed from keratin biomaterials |
US8785370B2 (en) | 2007-10-05 | 2014-07-22 | Keratin Complex Holdings, Inc. | Reactive keratin protein formulations and methods of using for revitalizing hair |
US20090211593A1 (en) * | 2007-10-05 | 2009-08-27 | Peter Coppola | Reactive Keratin Protein Formulations and Methods of Using for Revitalizing Hair |
WO2013025941A1 (en) * | 2011-08-17 | 2013-02-21 | Keranetics Llc | Low protein percentage gelling compositions |
US9700631B2 (en) | 2011-08-17 | 2017-07-11 | KeraNetics, LLC | Low protein percentage gelling compositions |
US10279045B2 (en) | 2011-08-17 | 2019-05-07 | Keranetics Llc | Low protein percentage gelling compositions |
US10385095B2 (en) | 2011-08-17 | 2019-08-20 | Keratin Biosciences, Inc | Methods for extracting keratin proteins |
US10709789B2 (en) | 2011-08-17 | 2020-07-14 | KeraNetics, Inc. | Low protein percentage gelling compositions |
US11034722B2 (en) | 2011-08-17 | 2021-06-15 | KeraNetics, Inc. | Methods for extracting keratin proteins |
US9827245B2 (en) | 2013-03-15 | 2017-11-28 | KeraNetics, LLC | Keratin compositions comprising halofuginone |
Also Published As
Publication number | Publication date |
---|---|
DE60015807D1 (en) | 2004-12-16 |
EP1265570B1 (en) | 2004-11-10 |
DE60015807T2 (en) | 2005-11-24 |
WO2000076437A1 (en) | 2000-12-21 |
US6270791B1 (en) | 2001-08-07 |
JP2003501208A (en) | 2003-01-14 |
EP1265570A1 (en) | 2002-12-18 |
EP1265570A4 (en) | 2003-01-29 |
CA2376889A1 (en) | 2000-12-21 |
ATE281842T1 (en) | 2004-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6270791B1 (en) | Soluble keratin peptide | |
US5932552A (en) | Keratin-based hydrogel for biomedical applications and method of production | |
US6165496A (en) | Keratin-based sheet material for biomedical applications and method of production | |
US6159495A (en) | Porous and bulk keratin bio-polymers | |
US10821211B2 (en) | Coatings and biomedical implants formed from keratin biomaterials | |
US6274163B1 (en) | Keratinous protein material for wound healing applications and method | |
CN113301910B (en) | Skin rejuvenation and healing mixtures of peptide components and uses thereof | |
EP0462194B1 (en) | Fibroblast growth factor (fgf)-based stabilized compositions | |
ATE285787T1 (en) | ANTARTICINE-NF3 FOR THE TREATMENT AND REEPITHELIALIZATION OF WOUNDS | |
WO1990003797A1 (en) | Stabilized composition based on growth factors of the family fgf and on dextrane sulfate, and its applications | |
JPH0320206A (en) | Skin cosmetic | |
KR102503124B1 (en) | Method for preparing sheep placenta extract containing high content of amino acid and cosmetic composition comprising the extract | |
DE3147727C2 (en) | Wound healing agents containing collagen from basement membranes | |
MXPA00005252A (en) | Keratin-based hydrogel for biomedical applications and method of production | |
JPH0656692A (en) | Wound therapeutic agent comprising tcf-ii as active ingredient | |
KR20050006004A (en) | A cosmetic composition comprising Copper peptide | |
MXPA00005247A (en) | Method of cross-linking keratin-based films, sheets, and bulk materials | |
KR20010056177A (en) | Skin care composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KERAPLAST TECHNOLOGIES, LTD., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOUTHWEST RESEARCH INSTITUTE;REEL/FRAME:013465/0168 Effective date: 19991018 Owner name: SOUTHWEST RESEARCH INSTITUTE, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN DYKE, MARK E.;BLANCHARD, CHERYL R.;TIMMONS, SCOTT F.;AND OTHERS;REEL/FRAME:013465/0172 Effective date: 19991015 Owner name: KERAPLAST TECHNOLOGIES, LTD., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SMITH, ROBERT A.;REEL/FRAME:013465/0165 Effective date: 19990826 |
|
AS | Assignment |
Owner name: KMS VENTURES, INC., TEXAS Free format text: SECURITY INTEREST;ASSIGNOR:KERAPLAST TECHNOLOGIES, LTD.;REEL/FRAME:013248/0355 Effective date: 20020405 |
|
AS | Assignment |
Owner name: KMS VENTURES, INC., TEXAS Free format text: SECURITY INTEREST;ASSIGNOR:KERAPLAST TECHNOLOGIES, LTD.;REEL/FRAME:018654/0256 Effective date: 20061024 |
|
AS | Assignment |
Owner name: CRYMES G. PITTMAN, MICHIGAN Free format text: SECURITY AGREEMENT;ASSIGNOR:KERAPLAST TECHNOLOGEIS, LTD.;REEL/FRAME:018731/0432 Effective date: 20060221 Owner name: ROBERT E. GREY, MASSACHUSETTS Free format text: SECURITY AGREEMENT;ASSIGNOR:KERAPLAST TECHNOLOGEIS, LTD.;REEL/FRAME:018731/0432 Effective date: 20060221 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |